Phathom Pharmaceuticals(PHAT) - 2024 Q1 - Quarterly Results

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 "Phathom is quickly establishing VOQUEZNA as the first and only FDA-approved treatment of its kind for Erosive GERD and we are thrilled with the promising strides made in our first full quarter post-launch," said Terrie Curran, President and CEO of Phathom. "We're pleased that prescribers are embracing VOQUEZNA as a powerful new treatment option and that demand is rapidly growing. The positive feed ...